Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SNDA vs AMS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SNDA Captures Overall Composite Edge (44.1 HOLD vs 33.8 SELL), While AMS Leads 3–2 on Growth & Valuation Pillars

SNDA Overall Winner 6-Pillar Tally: SNDA 2 – 3 AMS (1 Tie) Matrix Metrics: SNDA 5 – 5 AMS

As of Nov 16, 2026, Sonida Senior Living, Inc. (SNDA) captures the overall head-to-head institutional edge over American Shared Hospital Services (AMS) on higher Unified Composite conviction (44.1/100 HOLD vs. 33.8/100 SELL) after splitting the core matrix 5–5 (led by Growth & Scale, Balance Sheet & Cash Flow), while AMS wins 3–2 across the 6-pillar growth and valuation breakdown. SNDA trades at $32.90 (57.1x Forward P/E, -3.1% operating margin) versus AMS at $1.07 (44.6x Forward P/E, -7.4% operating margin).

  • Growth vs. Quality Trade-Off: SNDA earns the overall head-to-head edge with a stronger Unified Composite Score (44.1/100 HOLD vs. AMS 33.8/100 SELL) and 0.49β · 49% Vol risk profile, whereas AMS leads top-line expansion (+19.2% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: SNDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.9); meanwhile AMS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SNDA vs AMS
SNDA NYSE Head-to-Head Winner
Sonida Senior Living, Inc.
Services-Nursing & Personal Care Facilities
$32.90
-0.3% 1D
Market Cap $1.6B
TTM Revenue $594M
Forward P/E 57.1x
Beta / 30D Vol 0.49β · 49% Vol
Unified Composite Score
44.1 / 100 HOLD
Tech 47.0 Fund 52.0 Flow 50.0 Mom 58.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.6%), weak momentum, RSI 41
RSI-14: 40.9 · SMA20: $33.79 · SMA50: $36.03
AMS NYSE American
American Shared Hospital Services
Services-Medical Laboratories
$1.07
-0.93% 1D
Market Cap $7.2M
TTM Revenue $30M
Forward P/E 44.6x
Beta / 30D Vol 0.18β · 46% Vol
Unified Composite Score
33.8 / 100 SELL
Tech 24.0 Fund 38.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.9%), weak momentum, RSI 27
RSI-14: 27.1 · SMA20: $1.21 · SMA50: $1.32

6-Pillar Scorecard Institutional Category Breakdown (SNDA 2 – 3 AMS)

Columns: Metric · SNDA · AMS
1. Valuation Multiples AMS
Forward P/E 57.1x 44.6x
Trailing P/E 57.1x 44.6x
PEG Ratio 2.04x N/M
EV / Revenue 2.7x 0.8x
2. Growth & Scale SNDA
Revenue Growth (YoY) +131.2% +19.2%
Earnings Growth (YoY) -21.7% -38.1%
TTM Revenue (USD) $594M $30M
Market Cap $1.6B $7.2M
3. Profitability & Quality AMS
Gross Margin 29.4% 34.8%
Operating Margin -3.1% -7.4%
Net Profit Margin -21.9% -5.8%
Return on Equity (ROE) -27.0% -12.1%
4. Balance Sheet & Cash Flow SNDA
Cash Generation (TTM) $103M EBITDA -$916,000
Cash Flow Margin 17.3% EBITDA Mgn -3.0%
Net Cash / Leverage $18.41 Book/Sh · -27.0% ROE $17M Net Debt (0.95x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat AMS
OpEx & R&D Intensity 32.5% of Rev ($193M) 42.2% of Rev ($13M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Care Facilities Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SNDA (5) vs AMS (5)
Institutional Metric SNDA AMS Criterion Row Edge
Market Capitalization
Scale
$1.6B $7.2M Larger Scale SNDA
Trailing P/E Ratio
Valuation
57.1x 44.6x Lower Multiple AMS
Forward P/E Ratio
Valuation
57.1x 44.6x Lower Multiple AMS
Revenue Growth (YoY)
Growth
+131.2% +19.2% Higher Growth SNDA
Operating Margin (TTM)
Profitability
-3.1% -7.4% Higher Margin SNDA
Net Profit Margin
Profitability
-21.9% -5.8% Higher Margin AMS
Return on Equity (ROE)
Capital Efficiency
-27.0% -12.1% Higher ROE AMS
52-Week Range Position
Momentum
22% ($30–$44) 6% ($1–$2) Stronger Trend SNDA
Beta / 30D Volatility
Risk Regime
0.49β · 49% Vol 0.18β · 46% Vol Lower Realized Risk AMS
Unified Institutional Score
Composite Signal
44.1 / 100 (HOLD) 33.8 / 100 (SELL) Higher Composite SNDA
Trailing 12M Revenue (USD)
Operating Scale
$594M $30M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
29.4% 34.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.04x PEG · 2.7x EV/Rev N/M PEG · 0.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$103M EBITDA ($18.41 Book/Sh · -27.0% ROE) -$916,000 ($17M Net Debt (0.95x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SNDA +9.64 pp
SNDA: -6.77% · AMS: -16.41%
3M Horizon SNDA +10.39 pp
SNDA: -18.75% · AMS: -29.14%
6M Horizon SNDA +12.63 pp
SNDA: -10.94% · AMS: -23.57%
1Y Horizon SNDA +55.01 pp
SNDA: +2.78% · AMS: -52.23%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SNDA vs AMS. Trailing 12-month operating profitability (SNDA -3.1% vs AMS -7.4%) and valuation multiples (SNDA 57.1x vs AMS 44.6x Forward P/E) are benchmarked directly in Pillar 4 below.

SNDA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$594M
Gross Margin29.4%
Op. Margin-3.1%
ROE / Fwd P/E-27.0% · 57.1x
AMS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$30M
Gross Margin34.8%
Op. Margin-7.4%
ROE / Fwd P/E-12.1% · 44.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SNDA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SNDA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AMS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AMS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SNDA Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $1.6B market capitalization and -3.1% operating margin.
OpEx & R&D Reinvestment 32.5% of Rev ($193M)
90D Engineering Disclosures 0 Published
AMS Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $7.2M market capitalization and -7.4% operating margin.
OpEx & R&D Reinvestment 42.2% of Rev ($13M)
90D Engineering Disclosures 0 Published
Mapped Supply-Chain Ecosystem (18 partners):
Taiwan Semiconductor Manufacturing Company GlobalFoundries ASE Technology Holding Amkor Technology

Investor FAQ SNDA vs AMS Key Questions & Quantitative Answers

As of Nov 16, 2026, Sonida Senior Living, Inc. (SNDA) captures the overall head-to-head institutional edge over American Shared Hospital Services (AMS) on higher Unified Composite conviction (44.1/100 HOLD vs. 33.8/100 SELL) after splitting the core matrix 5–5 (led by Growth & Scale, Balance Sheet & Cash Flow), while AMS wins 3–2 across the 6-pillar growth and valuation breakdown. SNDA trades at $32.90 (57.1x Forward P/E, -3.1% operating margin) versus AMS at $1.07 (44.6x Forward P/E, -7.4% operating margin). Growth vs. Quality Trade-Off: SNDA earns the overall head-to-head edge with a stronger Unified Composite Score (44.1/100 HOLD vs. AMS 33.8/100 SELL) and 0.49β · 49% Vol risk profile, whereas AMS leads top-line expansion (+19.2% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: SNDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.9); meanwhile AMS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SNDA leads the Growth & Scale pillar: SNDA posts +131.2% YoY revenue growth and -21.7% YoY earnings growth on $594M TTM revenue (29.4% gross margin, -3.1% operating margin), compared with AMS at +19.2% YoY revenue growth and -38.1% YoY earnings growth on $30M TTM revenue (34.8% gross margin, -7.4% operating margin). On trailing 12-month operating scale, SNDA generates $594M in USD-normalized revenue versus $30M for AMS. In operating R&D and SG&A reinvestment, SNDA deploys 32.5% of Rev ($193M) (0 90-day corporate R&D disclosures) versus 42.2% of Rev ($13M) (0 disclosures) for AMS.

AMS screens cheaper on headline valuation multiples. SNDA trades at 57.1x Forward P/E, 57.1x Trailing P/E, 2.04x PEG, and 2.7x EV/Revenue (17.3% EBITDA margin), whereas AMS trades at 44.6x Forward P/E, 44.6x Trailing P/E, N/M PEG, and 0.8x EV/Revenue (-3.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SNDA (-27.0% ROE) versus AMS (-12.1% ROE) capital efficiency.

In options market volatility and institutional positioning, SNDA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.49β · 49% Vol realized risk). By comparison, AMS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.18β · 46% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.